1 active not recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Unresectable Uterine Corpus Leiomyosarcoma: new trials by email Literature Review of Unresectable Uterine Corpus Leiomyosarcoma trials Research Report on Unresectable Uterine Corpus Leiomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2023-03-30 | 2026-10-01 |
Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Temozolomide (1) · Trabectedin (1) · olaparib (1) · pazopanib (1)
National Cancer Institute (NCI) (1)
Puerto Rico (1) · United States (1)
Matthew Ingham (1)
U10CA180821 (1)